Astrana Health, Inc (ASTH) PT Raised to $67 at Baird

Baird analyst Michael Ha raised the price target on Astrana Health, Inc (NASDAQ: ASTH) to $67.00 (from $54.00) while maintaining a Outperform rating.

The analyst commented: "Astrana (Top Pick) is grossly undervalued and on the precipice of unlocking a wealth of growth. Story is simple: we estimate full-risk conversion of most of its ~1m members can
drive ASTH to at least +24% Revenue and +21% adj. EBITDA three-year CAGR (from this lever alone). With full claims delegation, ASTH has unique visibility into member profitability helping to de-risk this opportunity. Trading at ~30% discount to PRVA but nearly 2x EBITDA and a path to unlocking greater growth, we believe the ASTH pitch is simple and the upside is attractive."

You May Also Be Interested In

• Shoe Station Group (SHOE) PT Lowered to $15 at Williams Trading
• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
• Oracle (ORCL) PT Lowered to $200 at Stifel, Buy Rating Maintained